555 related articles for article (PubMed ID: 31566258)
1. Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.
Kim B; Park JH; Sailor MJ
Adv Mater; 2019 Dec; 31(49):e1903637. PubMed ID: 31566258
[TBL] [Abstract][Full Text] [Related]
2. Theranostic Nanoparticles for RNA-Based Cancer Treatment.
Revia RA; Stephen ZR; Zhang M
Acc Chem Res; 2019 Jun; 52(6):1496-1506. PubMed ID: 31135134
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
Aghamiri S; Mehrjardi KF; Shabani S; Keshavarz-Fathi M; Kargar S; Rezaei N
Nanomedicine (Lond); 2019 Aug; 14(15):2083-2100. PubMed ID: 31368405
[TBL] [Abstract][Full Text] [Related]
4. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
[TBL] [Abstract][Full Text] [Related]
5. Budding Alliance of Nanotechnology in RNA Interference Therapeutics.
Kumawat A; Dapse P; Kumar N; Mishra DK; Maheshwari R; Bhattacharya P; Tekade RK
Curr Pharm Des; 2018; 24(23):2632-2643. PubMed ID: 30084328
[TBL] [Abstract][Full Text] [Related]
6. Direct cytoplasmic delivery of RNAi therapeutics through a non-lysosomal pathway for enhanced gene therapy.
Zhou J; Zhang J; Chen S; Lin Q; Zhu R; Wang L; Chen X; Li J; Yang H
Acta Biomater; 2023 Oct; 170():401-414. PubMed ID: 37625679
[TBL] [Abstract][Full Text] [Related]
7. PAMAM Dendrimers as a Delivery System for Small Interfering RNA.
Kheiriabad S; Ghaffari M; Dolatabadi JEN; Hamblin MR
Methods Mol Biol; 2020; 2115():91-106. PubMed ID: 32006396
[TBL] [Abstract][Full Text] [Related]
8. Delivery materials for siRNA therapeutics.
Kanasty R; Dorkin JR; Vegas A; Anderson D
Nat Mater; 2013 Nov; 12(11):967-77. PubMed ID: 24150415
[TBL] [Abstract][Full Text] [Related]
9. siRNA release kinetics from polymeric nanoparticles correlate with RNAi efficiency and inflammation therapy via oral delivery.
He C; Yue H; Xu L; Liu Y; Song Y; Tang C; Yin C
Acta Biomater; 2020 Feb; 103():213-222. PubMed ID: 31812844
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Delivery of siRNA to Retinal Ganglion Cells by Intravitreal Lipid Nanoparticles of Positive Charge.
Huang X; Chau Y
Mol Pharm; 2021 Jan; 18(1):377-385. PubMed ID: 33295773
[TBL] [Abstract][Full Text] [Related]
11. Stimuli-responsive hybrid nanocarriers developed by controllable integration of hyperbranched PEI with mesoporous silica nanoparticles for sustained intracellular siRNA delivery.
Prabhakar N; Zhang J; Desai D; Casals E; Gulin-Sarfraz T; Näreoja T; Westermarck J; Rosenholm JM
Int J Nanomedicine; 2016; 11():6591-6608. PubMed ID: 27994460
[TBL] [Abstract][Full Text] [Related]
12. Genetic pharmacology: progresses in siRNA delivery and therapeutic applications.
Scherman D; Rousseau A; Bigey P; Escriou V
Gene Ther; 2017 Mar; 24(3):151-156. PubMed ID: 28121307
[TBL] [Abstract][Full Text] [Related]
13. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
Ku SH; Kim K; Choi K; Kim SH; Kwon IC
Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy.
Babu A; Muralidharan R; Amreddy N; Mehta M; Munshi A; Ramesh R
IEEE Trans Nanobioscience; 2016 Dec; 15(8):849-863. PubMed ID: 28092499
[TBL] [Abstract][Full Text] [Related]
15. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
16. The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers.
Joo MK; Yhee JY; Kim SH; Kim K
J Control Release; 2014 Nov; 193():113-21. PubMed ID: 24862319
[TBL] [Abstract][Full Text] [Related]
17. A Review of pH-Responsive Organic-Inorganic Hybrid Nanoparticles for RNAi-Based Therapeutics.
Wang L; Yan Y
Macromol Biosci; 2021 Sep; 21(9):e2100183. PubMed ID: 34160896
[TBL] [Abstract][Full Text] [Related]
18. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
19. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.
Kim YD; Park TE; Singh B; Maharjan S; Choi YJ; Choung PH; Arote RB; Cho CS
Nanomedicine (Lond); 2015; 10(7):1165-88. PubMed ID: 25929572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]